Valeant Pharmaceuticals Faces New Fraud Lawsuit Filed by Former Investor
The pharmaceutical company allegedly shielded their branded drugs from generic competition and inflated their revenues using a fraudulent scheme. T. Rowe Price also declined to comment. The lawsuit points to Valeant’s alleged decisions to massively increase prices of so-called “orphan drugs” to treat rare medical conditions that face little or no competition and “back door” efforts to receive …